The Penn Transplant Institute's three-part virtual CME series returns this fall to mark the continuation of this fascinating and informative forum for physicians and specialists with a focus on liver transplantation.
Beginning with an overview of living donor liver transplantation, its benefits, and the requisites of donor selection, the Liver Transplant Virtual CME Series will delve into the selection process and treatment protocols for liver transplantation in hepatocellular carcinoma and cholangiocarcinoma and conclude with an overview of the most common indication for liver transplantation, alcohol-associated liver disease, to further an understanding of the condition's prevalence and the selection criteria for liver transplantation and outcomes for the procedure in individuals with alcohol-associated hepatitis.
The virtual sessions are conveniently scheduled during evening hours and are open to all healthcare providers treating end-stage liver disease and alcohol use disorder.
Living Donor Liver Transplantation: Maximizing Opportunities & Safety
Session Recording
Faculty
Kim Olthoff, MD, Chief of the Division of Transplant Surgery and Therese Bittermann, MD, MSCE, Medical Director of the Living Donor Liver Program present session one of this year's Liver Transplant Virtual CME Series to examine the benefits of living donor liver transplantation (LDLT) in light of the continuing shortage of deceased liver donors and the critical need to identify appropriate recipients and candidates for living liver donation.
This session reviews the referral process for LDLT recipients and the donor selection and evaluation process, as well as offers an in-depth understanding of the short- and long-term outcomes for LDLT donors and recipients.
You can view the session recording above. Please note that CME credit is no longer available for session one of the series.
Pushing the Envelope for Cancer Cure: Liver Transplant for Liver Cancer
Session Recording
Faculty
Peter L. Abt, MD, and Maarouf A. Hoteit, MD, share their perspectives on liver transplantation as an ideal treatment for early stage nonresectable hepatocellular carcinoma (HCC), review local regional therapy for down-staging of HCC tumors exceeding standard criteria for transplant, and offer insight on the selection criteria and treatment protocols for liver transplantation in cholangiocarcinoma, formerly an absolute contraindication to transplantation.
You can view the session recording above. Please note that CME credit is no longer available for session one of the series.
Liver Transplant for Alcohol-Associated Liver Disease: Moving Beyond the "6-Month Rule"
Faculty
Session three of this year's Liver Transplant Virtual CME Series focuses on the prevalence of alcohol-associated liver disease (ALD), currently the leading indication for liver transplantation in the United States.
Penn Medicine's Kenneth D. Rothstein, MD, Ethan Weinberg, MD, MS, and Jonathan Dante Nahas, MD review the objective criteria used in the pre-transplant setting to select appropriate patients for liver transplantation and offer an overview of the provider-dependent variables in referral for liver transplantation evaluation in the ALD population with a focus on improving the timing for liver transplantation referral to ensure equal access to waitlist evaluation with respect to the principles of equity, justice, and transparency.
You can view the session recording above. Please note that CME credit is no longer available for session one of the series.
Additional Resources from the Penn Transplant Institute